The company has developed nanocapsule technology that can reach the most challenging disease sites in the body, delivering cargo intact into the nucleus of target cells. The technology has been proven through research and development by GeneSegues Therapeutics and has been initially developed for solid tumor cancers of the head and neck, prostate, and colon. RoverMed is now partnering with larger drug developers to expand the acceptance, use, and impact of the technology on a range of new applications. The company's business model includes collaborating with partners to advance novel therapeutics for diseases that are not well served by traditional treatment options.